AP2013007178A0 - BCMA-based stratification and therapy for multiplemyeloma patients - Google Patents

BCMA-based stratification and therapy for multiplemyeloma patients

Info

Publication number
AP2013007178A0
AP2013007178A0 AP2013007178A AP2013007178A AP2013007178A0 AP 2013007178 A0 AP2013007178 A0 AP 2013007178A0 AP 2013007178 A AP2013007178 A AP 2013007178A AP 2013007178 A AP2013007178 A AP 2013007178A AP 2013007178 A0 AP2013007178 A0 AP 2013007178A0
Authority
AP
ARIPO
Prior art keywords
multiplemyeloma
bcma
therapy
patients
based stratification
Prior art date
Application number
AP2013007178A
Other languages
English (en)
Inventor
Jasmin Barbara Hebeis
Eric Borges
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44343806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2013007178(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AP2013007178A0 publication Critical patent/AP2013007178A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AP2013007178A 2011-04-21 2012-04-20 BCMA-based stratification and therapy for multiplemyeloma patients AP2013007178A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11163558 2011-04-21
PCT/EP2012/057248 WO2012143498A1 (en) 2011-04-21 2012-04-20 Bcma-based stratification and therapy for multiple myeloma patients

Publications (1)

Publication Number Publication Date
AP2013007178A0 true AP2013007178A0 (en) 2013-10-31

Family

ID=44343806

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013007178A AP2013007178A0 (en) 2011-04-21 2012-04-20 BCMA-based stratification and therapy for multiplemyeloma patients

Country Status (19)

Country Link
US (3) US20130101599A1 (enExample)
EP (1) EP2699259B1 (enExample)
JP (1) JP2014520248A (enExample)
KR (1) KR20140031905A (enExample)
CN (1) CN103608039A (enExample)
AP (1) AP2013007178A0 (enExample)
AU (1) AU2012244676A1 (enExample)
CA (1) CA2832510A1 (enExample)
CL (1) CL2013003031A1 (enExample)
CO (1) CO6801644A2 (enExample)
EA (1) EA201301180A1 (enExample)
IL (1) IL228701A0 (enExample)
MA (1) MA35056B1 (enExample)
MX (1) MX2013012167A (enExample)
PE (1) PE20140612A1 (enExample)
PH (1) PH12013502147A1 (enExample)
SG (1) SG194500A1 (enExample)
TN (1) TN2013000412A1 (enExample)
WO (1) WO2012143498A1 (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013340799B2 (en) 2012-11-01 2018-08-09 Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) An antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
EP2953974B1 (en) 2013-02-05 2017-12-20 EngMab Sàrl Bispecific antibodies against cd3epsilon and bcma
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
US10126301B2 (en) * 2013-02-08 2018-11-13 Institute For Myeloma & Bone Cancer Research Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and B-cell non-hodgkin lymphoma
KR102480433B1 (ko) 2014-02-07 2022-12-21 맥마스터 유니버시티 3기능성 t 세포-항원 커플러 및 이의 제조 방법 및 용도
KR102632731B1 (ko) * 2014-04-30 2024-02-01 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Ｃｄ269에 대한 인간화 항체
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) * 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
EP3227432B1 (en) 2014-12-05 2023-10-11 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
KR102701479B1 (ko) 2014-12-05 2024-09-03 메모리얼 슬로안 케터링 캔서 센터 B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
TWI703159B (zh) * 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
HRP20200390T1 (hr) 2015-08-03 2020-06-12 Engmab Sàrl Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
UA127515C2 (uk) 2015-08-17 2023-09-20 Янссен Байотек, Інк. Антитіло до всма, біспецифічна антигензв'язувальна молекула, що зв'язує всма і cd3, і їх використання
EP3368903A1 (en) * 2015-10-30 2018-09-05 GlaxoSmithKline Intellectual Property Development Limited Prognostic method
ES2898329T3 (es) 2016-01-12 2022-03-07 Oncotracker Inc Métodos mejorados para supervisar el estado inmunitario de un sujeto
CN116063503A (zh) 2016-02-17 2023-05-05 思进股份有限公司 Bcma抗体和其用以治疗癌症和免疫病症的用途
WO2017223111A1 (en) 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies
MY200988A (en) 2016-09-14 2024-01-27 Teneobio Inc CD3 Binding Antibodies
IL266424B2 (en) * 2016-11-02 2023-09-01 Engmab Sarl A bispecific antibody against bcma and cd3 and an immunological drug for combined treatment in multiple myeloma
EP3559035A1 (en) * 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018151836A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018231944A1 (en) 2017-06-13 2018-12-20 Berenson James R Diagnostic, prognostic, and monitoring methods for solid tumor cancers
US20200384130A1 (en) 2017-06-14 2020-12-10 Dana-Farber Cancer Institute, Inc. B-cell maturation antigen (bcma)-directed nanoparticles
CA3067584A1 (en) 2017-06-20 2018-12-27 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
CN118146370A (zh) 2017-06-20 2024-06-07 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3692066A2 (en) * 2017-09-14 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer
JP7137619B2 (ja) * 2017-09-29 2022-09-14 モガム・インスティテュート・フォー・バイオメディカル・リサーチ Ｂｃｍａに対して高い親和性を有する抗ｂｃｍａ抗体およびそれを含むがんの処置のための医薬組成物
WO2019071358A1 (en) 2017-10-12 2019-04-18 Mcmaster University Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
IL321733A (en) 2017-10-18 2025-08-01 Novartis Ag Compositions and methods for selective degradation of proteins
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
MA49911A (fr) * 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
MX2020004568A (es) 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.
EP3710040A1 (en) 2017-11-15 2020-09-23 Novartis AG Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
JP2021509009A (ja) 2017-11-30 2021-03-18 ノバルティス アーゲー Ｂｃｍａターゲティングキメラ抗原受容体及びその使用
US20200368268A1 (en) 2018-01-08 2020-11-26 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
MX2020012286A (es) 2018-05-16 2021-04-28 Janssen Biotech Inc Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t.
EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP3844267B1 (en) 2018-08-31 2025-06-25 Novartis AG Methods of making chimeric antigen receptor-expressing cells
WO2020089794A1 (en) * 2018-10-31 2020-05-07 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
WO2020176397A1 (en) 2019-02-25 2020-09-03 Novartis Ag Mesoporous silica particles compositions for viral delivery
US20230074800A1 (en) 2019-03-21 2023-03-09 Novartis Ag Car-t cell therapies with enhanced efficacy
EA202192736A1 (ru) 2019-04-05 2022-01-27 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с псма
US20220168389A1 (en) 2019-04-12 2022-06-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
CU20210096A7 (es) 2019-05-21 2022-06-06 Novartis Ag Moléculas de unión a cd19
PH12021553145A1 (en) 2019-06-14 2022-07-25 Teneobio Inc Multispecific heavy chain antibodies binding to cd22 and cd3
PH12022551291A1 (en) 2019-11-26 2023-11-20 Novartis Ag Chimeric antigen receptors binding bcma and cd19 and uses thereof
CA3166629A1 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
BR112022017148A2 (pt) 2020-02-27 2022-11-08 Novartis Ag Métodos para produzir células que expressam receptor de antígeno quimérico
CN115397460A (zh) 2020-02-27 2022-11-25 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
AU2021272291A1 (en) 2020-05-11 2023-02-02 Janssen Biotech, Inc. Methods for treating multiple myeloma
KR20230013258A (ko) 2020-05-19 2023-01-26 얀센 바이오테크 인코포레이티드 T 세포 재유도 치료제 및 vla-4 부착 경로 억제제를 포함하는 조성물
CA3185455A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
PE20230464A1 (es) 2020-06-30 2023-03-14 Teneobio Inc Union de anticuerpos multiespecificos a bcma
AU2021329404A1 (en) 2020-08-21 2023-04-20 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
CN112698037B (zh) * 2021-03-25 2021-06-25 北京积水潭医院 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用
US20250099579A1 (en) 2021-04-08 2025-03-27 Marengo Therapeutics, Inc. Multispecific molecules binding to tcr and uses thereof
AU2022267891A1 (en) 2021-04-27 2023-11-09 Novartis Ag Viral vector production system
CA3173810A1 (en) 2021-06-01 2022-12-01 Andreas Bader Claudin 18.2 t cell-antigen couplers and uses thereof
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
US20250000973A1 (en) 2021-08-20 2025-01-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CA3237357A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
WO2024025967A1 (en) * 2022-07-28 2024-02-01 Springworks Therapeutics, Inc. Determination of bcma level on plasma cells by flow cytometry
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
CA2720682A1 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
NZ594985A (en) * 2009-03-10 2013-07-26 Biogen Idec Inc Anti-bcma (b-cell maturation antigen, cd269, tnfrsf17) antibodies
WO2010121093A2 (en) 2009-04-17 2010-10-21 Lpath, Inc. Humanized antibody compositions and methods for binding lysophosphatidic acid

Also Published As

Publication number Publication date
US20130101599A1 (en) 2013-04-25
CA2832510A1 (en) 2012-10-26
KR20140031905A (ko) 2014-03-13
CO6801644A2 (es) 2013-11-29
CL2013003031A1 (es) 2014-08-18
EP2699259B1 (en) 2016-07-27
JP2014520248A (ja) 2014-08-21
MX2013012167A (es) 2013-12-10
TN2013000412A1 (en) 2015-03-30
IL228701A0 (en) 2013-12-31
PE20140612A1 (es) 2014-06-07
US20140193433A1 (en) 2014-07-10
WO2012143498A1 (en) 2012-10-26
EA201301180A1 (ru) 2014-03-31
US20160131655A1 (en) 2016-05-12
SG194500A1 (en) 2013-12-30
CN103608039A (zh) 2014-02-26
EP2699259A1 (en) 2014-02-26
MA35056B1 (fr) 2014-04-03
AU2012244676A1 (en) 2013-10-24
PH12013502147A1 (en) 2014-01-13

Similar Documents

Publication Publication Date Title
AP2013007178A0 (en) BCMA-based stratification and therapy for multiplemyeloma patients
EP2739144A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
ZA201305897B (en) Combination therapy
EP2699199A4 (en) SYSTEMS AND METHODS FOR BARIATRIC THERAPY
GB201120993D0 (en) Novel compounds and their use in therapy
ZA201403372B (en) Therapeutic agents and uses thereof
ZA201400120B (en) Combination therapy
SI2780332T1 (sl) Morfolinilbenzotriazini za uporabo pri terapiji raka
ZA201502595B (en) Therapeutic methods
EP2701744A4 (en) COMBINATION THERAPY
GB201005394D0 (en) Therapy
IL228589A0 (en) Medical Care
GB201016864D0 (en) Therapeutic methods
GB201102226D0 (en) Inventions and therapy
GB201102234D0 (en) Inventions and therapy
GB201102232D0 (en) Inventions and therapy
GB201102239D0 (en) Inventions and therapy
GB201102231D0 (en) Inventions and therapy
GB201102227D0 (en) Inventions and therapy
GB201102221D0 (en) Inventions and therapy
GB201102238D0 (en) Inventions and therapy
GB201102236D0 (en) Inventions and therapy
GB201102228D0 (en) Inventions and therapy
GB201102215D0 (en) Inventions and therapy
GB201102213D0 (en) Inventions and therapy